Bispecific Antibody Emicizumab for Haemophilia A: A Breakthrough for Patients with Inhibitors. [electronic resource]
Producer: 20190503Description: 561-570 p. digitalISSN:- 1179-190X
- Antibodies, Bispecific -- therapeutic use
- Antibodies, Monoclonal, Humanized -- therapeutic use
- Blood Coagulation Factors -- adverse effects
- Clinical Trials, Phase III as Topic
- Coagulants -- therapeutic use
- Drug Therapy, Combination -- adverse effects
- Factor VIII -- genetics
- Health Services Needs and Demand
- Hemophilia A -- complications
- Hemorrhage -- epidemiology
- Humans
- Life Expectancy
- Quality of Life
- Thrombotic Microangiopathies -- chemically induced
- Treatment Outcome
No physical items for this record
Publication Type: Journal Article; Review
There are no comments on this title.
Log in to your account to post a comment.